← Leaderboards
Kristina H Lewis
Harvard Pilgrim Health Care, Inc.
$7,353,754
Attributed
$12,317,712
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2017–25$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,317,712 · 4
By mechanism
UH3$6,684,343 · 1
R01$3,867,210 · 2
UG3$1,766,159 · 1
Top collaborators
- Jamy D Ard5 shared
- Darren Toh2 shared
Most similar at Harvard Pilgrim Health Care, Inc.
Same institution · by research overlap
- Richard Platt$32,063,474
- Emily Oken$36,323,608
- Darren Toh$4,306,783
- Steven R. Simon$961,185
- Xiaojuan Li$831,422
Others in their field
Other Emerging Leaders on “Cardiovascular System”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Lisa Newman · Research Triangle Institute$22,725,934
- Craig Reist · Research Triangle Institute$22,725,934
- Ashlin Bolton · Broad Institute, Inc.$19,699,069
Research focus
Cardiovascular SystemComorbidityAmericanEffectivenessBody Mass IndexBody Weight DecreasedClinical PracticeGuidelinesLifestyle InterventionObesityBody WeightCostDiabetes MellitusUnited StatesPharmaceutical PreparationsPatient-Focused OutcomesObservational StudyCessation Of LifeCardiovascular DiseasesEvidence BaseOutcome MeasureDrug PrescriptionsBariatric SurgeryBariatrics
Grant awards (12)
1/2, Clinical Coordinating Center for the Long-term Effectiveness of the Anti-obesity medication Phentermine: the LEAP Trial$1,509,689
UH3 · FY2025 · HL · contact PI
Comparative effectiveness of anti-obesity medications for cardiometabolic health outcomes and health services use$707,430
R01 · FY2025 · HL
1/2, Clinical Coordinating Center for the Long-term Effectiveness of the Anti-obesity medication Phentermine: the LEAP Trial$1,515,457
UH3 · FY2024 · HL · contact PI
Comparative effectiveness of anti-obesity medications for cardiometabolic health outcomes and health services use$769,985
R01 · FY2024 · HL
1/2, Clinical Coordinating Center for the Long-term Effectiveness of the Anti-obesity medication Phentermine: the LEAP Trial$1,810,070
UH3 · FY2023 · HL · contact PI
1/2, Clinical Coordinating Center for the Long-term Effectiveness of the Anti-obesity medication Phentermine: the LEAP Trial$1,849,127
UH3 · FY2022 · HL · contact PI
1/2, Clinical Coordinating Center for the Long-term Effectiveness of the Anti-obesity medication Phentermine: the LEAP Trial$1,766,159
UG3 · FY2021 · HL · contact PI
Clinical and Health Care Use Outcomes for Vertical Sleeve Gastrectomy vs. Roux-en-Y Gastric Bypass Using a National Commercial Insurance Claims Dataset$453,381
R01 · FY2021 · DK · contact PI
Clinical and Health Care Use Outcomes for Vertical Sleeve Gastrectomy vs. Roux-en-Y Gastric Bypass Using a National Commercial Insurance Claims Dataset$489,759
R01 · FY2020 · DK · contact PI
Clinical and Health Care Use Outcomes for Vertical Sleeve Gastrectomy vs. Roux-en-Y Gastric Bypass Using a National Commercial Insurance Claims Dataset$453,381
R01 · FY2019 · DK · contact PI
Clinical and Health Care Use Outcomes for Vertical Sleeve Gastrectomy vs. Roux-en-Y Gastric Bypass Using a National Commercial Insurance Claims Dataset$450,960
R01 · FY2018 · DK · contact PI
Clinical and Health Care Use Outcomes for Vertical Sleeve Gastrectomy vs. Roux-en-Y Gastric Bypass Using a National Commercial Insurance Claims Dataset$542,314
R01 · FY2017 · DK · contact PI